Table 3. . Treatments persistence [13].

Year	RIS-GR Mean (95% CI)	ALN Mean (95% CI)
1	31.0% (29.3–32.8%)	37.2% (35.4–39.0%)
2	19.5% (18.1–21.0%)	25.6% (24.0–27.3%)
3	11.6% (10.3–12.8%)	18.2% (16.8–19.8%)
4	6.6% (5.5–7.7%)	12.6% (11.3–14.1%)
5	3.8% (2.9–4.9%)	9.1% (7.7–10.5%)

ALN: Weekly alendronate 70 mg tablets; CI: Confidence interval; RIS-GR: Weekly risedronate 35 mg gastro-resistant tablets.